bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: O S A J J M A M F J
2013: D N O

 
  Other news for:
Leukemia
 Resources from HONselect
Gazyva Approved for Chronic Lymphocytic Leukemia
A cancer of the blood and bone marrow

By Scott Roberts

FRIDAY, Nov. 1 (HealthDay News) -- Gazyva (obinutuzumab) has been approved by the U.S. Food and Drug Administration in combination with the anti-cancer drug chlorambucil for people with previously untreated chronic lymphocytic leukemia (CLL).

CLL is a progressive cancer of the blood and bone marrow. Some 15,680 Americans are likely to be diagnosed and 4,580 are projected to die from the disease this year, the U.S. National Cancer Institute estimates.

Gazyva is designed to bolster the immune system's ability to attack cancer cells, the FDA said in a news release. The agency said it granted the drug so-called "breakthrough therapy" status, since clinical evidence indicates it "may offer a substantial improvement over available therapies."

Approval was based on clinical studies of 356 people. Those receiving the Gazyva/chlorambucil combination had an average of 23 months of progression-free survival, compared with 11.1 months among participants who received chlorambucil alone, the FDA said.

The most common side effects of Gazyva were anti-drug reactions, a decrease in white blood cells, low blood platelets and/or red blood cells, muscle pain and fever.

Gazyva's label contains a boxed warning that it could trigger a "reactivation" of the Hepatitis B virus, and it may increase users' risk of a rare neurological disorder called progressive multifocal leukoencephalopathy.

Gazyva is marketed by Genentech, based in San Francisco.

More information

The National Cancer Institute has more about CLL.

Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=681761

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Leukemia
Leukemia, Lymphocytic
Blood
Neoplasms
Bone Marrow
Chlorambucil
Cells
Blood Cells
Bone and Bones
Blood Platelets
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact